Focal Segmental Glomerulosclerosis Drugs Market Report 2026

The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $17 billion in 2025 to $18.58 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to limited treatment options, high prevalence of kidney diseases, reliance on corticosteroids, increasing awareness of fsgs, advancements in immunosuppressive drugs.

The focal segmental glomerulosclerosis drugs market size is expected to see rapid growth in the next few years. It will grow to $27.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to growth in biologics and monoclonal antibodies, rise in personalized medicine approaches, expansion of rare disease research funding, technological integration in treatment development, increase in healthcare infrastructure in emerging markets. Major trends in the forecast period include personalized medicine development, targeted therapeutics research, rare disease drug pipeline expansion, clinical trial optimization, immunomodulatory therapy advancements.

Rising healthcare expenditure is expected to drive the growth of the focal segmental glomerulosclerosis (FSGS) drugs market in the coming years. Healthcare expenditure refers to the total amount of money spent on healthcare services, related goods, and activities within a specific healthcare system or economy over a defined period. Increasing healthcare spending supports the development and availability of drugs for focal segmental glomerulosclerosis (FSGS) by boosting research funding and clinical trials, which in turn enhance drug output. For instance, in November 2023, the Canadian Institute for Health Information, a Canada-based health information agency, reported that total health spending in Canada in 2023 was projected to reach $344 billion, equating to $8,740 per person. This represents a 2.8% increase compared to the previous year, which saw only a 1.5% growth in health spending in 2022, indicating a significant rebound in healthcare investment. Therefore, rising healthcare expenditures are propelling growth in the focal segmental glomerulosclerosis (FSGS) drugs market.

Major companies in the focal segmental glomerulosclerosis (FSGS) market are increasingly focusing on product development and innovation to deliver reliable treatments to patients and strengthen their market position. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched FILSPARI for focal segmental glomerulosclerosis (FSGS), which received approval from the Food and Drug Administration (FDA), a US-based federal agency. FILSPARI is an oral medication for treating IgA nephropathy (IgAN) and is the first and only non-immunosuppressive therapy for reducing proteinuria in IgAN, a rare kidney disease. Additionally, FILSPARI has received orphan drug designation in the United States and Europe for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).

In October 2023, Amgen, a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen aims to strengthen Horizon’s product portfolio, which includes key medications such as Tepezza and Krystexxa, used for treating rare inflammatory conditions. Horizon Therapeutics is a US-based biotechnology company involved in the development of focal segmental glomerulosclerosis drugs.

Major companies operating in the focal segmental glomerulosclerosis drugs market are Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio, Alexion Pharmaceuticals, Bayer AG, Novartis AG, Pfizer Inc., Johnson and Johnson Ltd., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Fresenius Kabi Ltd., Gilead Sciences Inc, Reata Pharmaceuticals, Amgen Inc.

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2025. The regions covered in the focal segmental glomerulosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the focal segmental glomerulosclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the focal segmental glomerulosclerosis drugs market by increasing the cost of imported raw materials, active pharmaceutical ingredients, and biologics manufacturing equipment. The resulting cost pressures have slowed production and delayed drug availability, particularly affecting regions like North America and Europe that rely on international suppliers. Segments such as monoclonal antibodies and immunosuppressive drugs are most affected. However, tariffs have encouraged local manufacturing and sourcing strategies, potentially reducing dependency on imports and fostering regional production capabilities.

The focal segmental glomerulosclerosis drugs market research report is one of a series of new reports that provides focal segmental glomerulosclerosis drugs market statistics, including focal segmental glomerulosclerosis drugs industry global market size, regional shares, competitors with a focal segmental glomerulosclerosis drugs market share, detailed focal segmental glomerulosclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the focal segmental glomerulosclerosis drugs industry. This focal segmental glomerulosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that leads to scarring of the kidney’s filtering units. Drugs for focal segmental glomerulosclerosis (FSGS) are medications used to treat the condition and manage its progression.

The main types of focal segmental glomerulosclerosis drugs include losmapimod, SHP-627, sparsentan, TM-5484, and others. Losmapimod is an investigational drug classified as a p38 mitogen-activated protein kinase (MAPK) inhibitor. Treatments include corticosteroids, immunosuppressive drugs, ACE inhibitors, AR blockers, diuretics, and others, administered through oral or parenteral routes. These drugs are used by end users such as hospitals, home care providers, specialty clinics, and others.

The focal segmental glomerulosclerosis (FSGS) drugs market consists of sales of rituximab, statins, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.